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in 100% cases. All patients were treated with crystalloids, sorbents,
croseltamivir and antibiotics.
Conclusion:Weassume that diarrhea in patientswith inﬂuenza
B in majority of cases associated with the development or worsen-
ing of common immunosuppression and dysbiotic changes in the
intestine. It is often associated with bacterial complications.
http://dx.doi.org/10.1016/j.ijid.2016.02.959
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Thrombocytopenia and anti-platelet antibodies
in patients with chronic hepatitis C
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Background: One of the key position in hemostasis belongs to
surface platelet receptors (SPR) - glycoproteins (GP) Ia/IIa, Ib/IX and
IIb/IIIa. Antibodies to SPR can lead to development of thrombocy-
topenia in patients with chronic HCV-infection. However the role
of different types of antibodies in this process is unknown.
Aim: to estimate the role of different types of antibodies to sur-
face platelet receptors in HCV-associated thrombocytopenia.
Methods & Materials: he detection GP Ia/IIa, Ib/IX and IIb/IIIa
was made by the ELISA technique in patients with HCV and
thrombocytopenia (group 1, n=29), HCV without thrombocytope-
nia (group 2, n=28) and healthy people (group 3, n=32). All patients
were untreated with interferon and ribavirin.
Results: Anti-GP Ia/IIa were detected in 44,8±9,2% in 1th group,
3,6 ± 3,5% in 2th group, 12,5±5,8% in 3th group, p1-2<0,01, p1-
3<0,05. Anti-GP Ib/IX were indicated in 55,2±9,2% in 1th group,
10,7±5,8% in 2th group, and 28,1±7,9% in 3th group, p1-2<0,01,
p1-3<0,05. Anti- GP IIb/IIIa were recorded in the same groups in
24,1±8,0%, 17,8±7,3% and 25±7,6% accordingly without any statis-
tical difference (Fig. 1).
Mean optical density (MOD) of anti-GPIa/IIa in 1th group also
was more signiﬁcant than in 2th and 3th group (0,331±0,035,
0,208±0,015 and 0,217±0,012 accordingly, p1-2<0,01, p1-3<0,01).
More high level of anti- GPIb/IX MOD was also recorded in 1th
group than in 2th group (0,280±0,025 and 0,215±0,010 p<0,05),
no statistical evidence was found between 3th group and patients
in 1th and 2th groups. Investigation of anti-GP IIb/IIIa MOD also
Fig. 1. Frequencyof detection the antibodies toplatelet antigensGP IIb/IIIa, GP Ib/IX,
GPIa/IIa in different groups.
Fig. 2. Relative concentration of anti-platelet in different groups.
did not ﬁnd any statistical difference between patients with HCV-
infected patients (both groups) and healthy people (Fig. 2)
Conclusion: High frequency of revealing and signiﬁcant level
of MOD of anti-GP Ia/IIa и Ib/IX in HCV-infected patients with
thrombocytopenia demonstrated the evidence of damage in the
ﬁrst stages of primary hemostasis: adhesion of platelets to colla-
genwith support ofGP Ia/IIa and stabilizationof this aggregatewith
support of collagen-binding activity of GP Ib/IX (factor Von Wille-
brand) as well as more high risk of destruction platelets binding
with anti-GP Ia/IIa and anti- GP Ib/IX in spleen. Detection of anti-
GP Ia/IIa и Ib/IX can serve as prognostication criteria for developing
thrombocytopenia in patients with chronic HCV-infection.
http://dx.doi.org/10.1016/j.ijid.2016.02.960
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Background: Hepatitis C virus (HCV) infection is a major health
problem worldwide. India has a burden of over 10 million HCV
chronic carriers. The previous standard of care for HCV was pegy-
lated IFN (Peg IFN) and ribavirin (RBV). The new direct acting
antivirals that are now available promise sustained virological
response, tolerability and higher cure rates. This study aims to
look at the response to sofosbuvir (SOF) (an NS5B nucleotide ana-
log) in combination with RBV with/ without Peg IFN among Indian
patients.
Methods & Materials: Plasma from 44 patients (including 5
post transplant) was obtained from those who were treated with
SOF and RBV ± PegIFN. RNA extraction and ampliﬁcation was done
using real time PCR. HCV genotypes were ascertained using the
NS5B region based sequencing. Samples were tested for RNA nega-
tivity, onemonthafter treatment initiation (RVR), and3 to6months
later.
Results: Thirty eight of 44 patients were genotyped. Genotype
distribution was 7(18.4%) for type 1, 28(73.7%)for type3, 3(9%) for
type 4 respectively. Patients with 1, 3 & 4 genotypes on additional
Peg IFN was 4(10.5%), 5(14.7%) & 1(2.94%) and without Peg IFN was
3(7.9%), 23(60.5%)&2(5.9%). RVR for all patientswas100%andat≥3
month follow up, there was 100% response to SOF based therapy.
RVR for the 5 post transplant patients was 100%.
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Conclusion: This preliminary study in this tertiary care centre
shows a 100% rapid virus response to SOF based therapy irrespec-
tive of genotype and transplant status among Indian patients. Long
term prospective studies are warranted to estimate sustained viro-
logical response to Sofosbuvir in Indian patients
http://dx.doi.org/10.1016/j.ijid.2016.02.961
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Serum levels of soluble CD26, a novel prognostic
marker for acute hepatitis E infection
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Background: Even without treatment, most of acute hepatitis
E virus (HEV) infected patients resolve HEV but sometimes the dis-
ease leads to acute liver failure, chronic infection, or extrahepatic
symptoms. Themechanisms of HEVpathogenesis appear to be sub-
stantially immune mediated. However, the immune responses to
HEV are not precisely identiﬁed. The aim of this study was evalua-
tion of Th1/Th2 ratio by determining serum soluble markers from
Th1 and Th2 cells in acute HEV infected patients.
Methods & Materials: This case control study included 35
acute HEV infected patients and 35 age and sex matched anti-HEV
negative healthy controls. The serum levels of IFN-g, IL-4, solu-
ble CD26 (sCD26) and sCD30 were determined by enzyme-linked
immunosorbent assay.
Results: The results showed a signiﬁcant difference in IFN-g and
sCD26 (P<0.0001 and P=0.001) but not IL-4 and sCD30 (P=0.354 and
P=0.159) between acute HEV patients and controls, respectively.
There was only a positive direct correlation between serum levels
of sCD26 and IFN-g in acute HEV patients (r=0.64, P=0.001). In addi-
tion, the ratio of sCD26/sCD30 in acute HEV group was more than
two fold higher than in HEV negative controls.
Conclusion: Acute HEV infection shows a pattern of Th1-type
immune response and a direct signiﬁcant positive correlation
between the serum level of sCD26 and IFN-g in acute HEV infected
patients, suggesting that the trend of sCD26 levels is a valuable
marker for predicting hepatic inﬂammation in hepatitis E.
http://dx.doi.org/10.1016/j.ijid.2016.02.962
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Splenic infarction, a rare complication of
infectious mononucleosis in a patient with no
signiﬁcant comorbidity: Case report and review
of the literature
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Background: We report a case of a 32-y-old male diagnosed
with infectious mononucleosis with splenomegaly complicated by
splenic infarct in second week of illness documented by abdominal
CT scan.
Methods & Materials: Infectious mononucleosis is commonly
caused by an Epstein – Barr virus (EBV) infection. The clinical syn-
drome usually presents with the classic triad of pharyngitis, fever,
and lymphadenopathy. Hepatosplenomegaly is also common. [1].
Splenic infarction represents a very rare complication of
infectious mononucleosis, encountered mostly in patients with
underlying comorbidities.
Results: A 32yr old male was admitted to our department
for high-grade fever and upper respiratory tract Infection for 10
days Cervical lymphadenopathy and hepatosplenomegalywas also
found during the physical examination and on abdominal ultra-
sound. Routine laboratory results showed a white blood cell count
of 5Kwith67% lymphocytes, including10%of atypical lymphocytes,
and elevated levels of aspartate aminotransferase, alanine amino-
transferase, and lactate dehydrogenase . Serologic viral screening
for hepatitis B and C viruses, human immunodeﬁciency virus ,
cytomegalovirus was negative. EBV was detected, EBV viral cap-
sid antigen immunoglobulin M (VCA-IgM) antibodies at high titers
. A monospot test was also positive.
On tenth day of illness patient complained of acute left upper
quadrant pain. Ultrasound examination revealed a hypoechogenic
area (5.1cm-3.2cm) in the enlarged spleen. Abdominal CT scan was
carried out and showed a splenic infarct (size 9.6 6.4 cm) (Fig-
ure 1). patient had negative Coombs’ tests, negative thrombophilic
screen (activated protein C resistance, protein C and S levels, lupus
anticoagulant, anticardiolipin, and anti- 2 glycoprotein I antibod-
ies)
Echocardiography, vasculitic proﬁle ANA, C- ANCA , P-ANCA and
bone marrow aspiration and biopsy were unremarkable.
The patient was managed symptomatically and showed resolu-
tion of infarct at 8 weeks.
Conclusion: Splenic infarction represents a very rare compli-
cation of infectious mononucleosis due to EBV infection. mostly
seen due to sickle-cell disease [2], pyruvate kinase deﬁ ciency [3]
autoimmunehaemolytic anaemia[4], , hereditary spherocytosis [5],
and protein C deﬁciency [6]. Acute EBV infection has recently been
recognized as a potential cause of splenic infarction, with or with-
out comorbidities studied in the largest series of patients with
splenic infarction [7].
http://dx.doi.org/10.1016/j.ijid.2016.02.963
